329 related articles for article (PubMed ID: 31707833)
1. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.
Lopes RD; Leonardi S; Wojdyla DM; Vora AN; Thomas L; Storey RF; Vinereanu D; Granger CB; Goodman SG; Aronson R; Windecker S; Thiele H; Valgimigli M; Mehran R; Alexander JH
Circulation; 2020 Mar; 141(9):781-783. PubMed ID: 31707833
[No Abstract] [Full Text] [Related]
2. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
[TBL] [Abstract][Full Text] [Related]
5. Critical appraisal of the AUGUSTUS trial.
Gremmel T; Sulzgruber P; Niessner A
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):187-188. PubMed ID: 31265054
[No Abstract] [Full Text] [Related]
6. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
[TBL] [Abstract][Full Text] [Related]
7. Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report.
Shoji K; Zen K; Ookura T; Yanishi K; Matoba S
BMC Cardiovasc Disord; 2021 Jan; 21(1):60. PubMed ID: 33516171
[TBL] [Abstract][Full Text] [Related]
8. Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy.
Galli M; Andreotti F; D'Amario D; Vergallo R; Montone RA; Porto I; Crea F
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):128-129. PubMed ID: 31309231
[No Abstract] [Full Text] [Related]
9. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
Vora AN; Alexander JH; Wojdyla DM; Aronson R; Granger CB; Darius H; Windecker S; Mehran R; Averkov O; Budaj A; Kong DF; Kobalava Z; Mehta RH; Mirza Z; Guimaraes PO; Parkhomenko A; Quadros A; Thiele H; Goodman SG; Lopes RD
Circulation; 2019 Dec; 140(23):1960-1963. PubMed ID: 31553201
[No Abstract] [Full Text] [Related]
10. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
[TBL] [Abstract][Full Text] [Related]
11. Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
Kang DO; Yu CW; Kim HD; Cho JY; Joo HJ; Choi RK; Park JS; Lee HJ; Kim JS; Park JH; Hong SJ; Lim DS
Coron Artery Dis; 2015 Aug; 26(5):372-80. PubMed ID: 25768244
[TBL] [Abstract][Full Text] [Related]
12. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
Welsh RC; Dehghani P; Lopes R; Wojdyla DM; Aronson R; Granger CB; Windecker S; Vora AN; Vinereanu D; Halvorsen S; Parkhomenko A; Mehran R; Alexander JH; Goodman S
Open Heart; 2022 Feb; 9(1):. PubMed ID: 35172988
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.
Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27803042
[TBL] [Abstract][Full Text] [Related]
14. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy for percutaneous coronary intervention in atrial fibrillation: standard of care, or a nightmare soon to end?
Verheugt FW
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S332-5. PubMed ID: 26149044
[TBL] [Abstract][Full Text] [Related]
16. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial.
Al-Khatib SM; Mulder H; Wojdyla D; Lopes RD; Wallentin L; Alexander JH; Hijazi Z; Goto S; Granger CB
Circ Arrhythm Electrophysiol; 2021 Mar; 14(3):e009614. PubMed ID: 33657831
[No Abstract] [Full Text] [Related]
17. [Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].
Geisler T; Gawaz M
MMW Fortschr Med; 2011 Apr; 153(15):27-30; quiz 31. PubMed ID: 21667556
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
Ng KH; Shestakovska O; Connolly SJ; Eikelboom JW; Avezum A; Diaz R; Lanas F; Yusuf S; Hart RG
Age Ageing; 2016 Jan; 45(1):77-83. PubMed ID: 26590293
[TBL] [Abstract][Full Text] [Related]
19. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
20. Apixaban for the prevention of stroke in atrial fibrillation.
Littrell R; Flaker G
Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
